- Home
- TAK vs NEM Comparison
TAK vs NEM Comparison
Compare TAK & NEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- NEM
- Stock Information
- Founded
- TAK 1781
- NEM 1916
- Country
- TAK Japan
- NEM United States
- Employees
- TAK N/A
- NEM N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- NEM Precious Metals
- Sector
- TAK Health Care
- NEM Basic Materials
- Exchange
- TAK Nasdaq
- NEM Nasdaq
- Market Cap
- TAK 42.2B
- NEM 47.2B
- IPO Year
- TAK N/A
- NEM N/A
- Fundamental
- Price
- TAK $14.87
- NEM $48.33
- Analyst Decision
- TAK
- NEM Buy
- Analyst Count
- TAK 0
- NEM 14
- Target Price
- TAK N/A
- NEM $53.58
- AVG Volume (30 Days)
- TAK 1.5M
- NEM 10.6M
- Earning Date
- TAK 05-08-2025
- NEM 04-24-2025
- Dividend Yield
- TAK 3.96%
- NEM 2.07%
- EPS Growth
- TAK 15.39
- NEM N/A
- EPS
- TAK 0.83
- NEM 2.92
- Revenue
- TAK $29,124,927,177.00
- NEM $18,682,000,000.00
- Revenue This Year
- TAK $8.53
- NEM $3.21
- Revenue Next Year
- TAK N/A
- NEM N/A
- P/E Ratio
- TAK $34.06
- NEM $16.54
- Revenue Growth
- TAK 9.83
- NEM 58.16
- 52 Week Low
- TAK $12.58
- NEM $36.10
- 52 Week High
- TAK $15.31
- NEM $58.72
- Technical
- Relative Strength Index (RSI)
- TAK 53.68
- NEM 63.47
- Support Level
- TAK $14.90
- NEM $47.14
- Resistance Level
- TAK $15.17
- NEM $49.52
- Average True Range (ATR)
- TAK 0.17
- NEM 1.19
- MACD
- TAK -0.07
- NEM 0.16
- Stochastic Oscillator
- TAK 21.43
- NEM 81.85
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About NEM Newmont Corporation
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.